12:00 AM
May 21, 2012
 |  BC Week In Review  |  Clinical News  |  Regulatory

Androxal enclomiphene regulatory update

Repros said FDA received the company's submission of required documentation for an SPA for 2 planned Phase III trials with oral Androxal enclomiphene to treat secondary hypogonadism....

Read the full 111 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >